[go: up one dir, main page]

WO2004016580A3 - Derives de l'acide r(+)-2-amino-3-hydroxypropanoique a action glycinergique - Google Patents

Derives de l'acide r(+)-2-amino-3-hydroxypropanoique a action glycinergique Download PDF

Info

Publication number
WO2004016580A3
WO2004016580A3 PCT/FR2003/002447 FR0302447W WO2004016580A3 WO 2004016580 A3 WO2004016580 A3 WO 2004016580A3 FR 0302447 W FR0302447 W FR 0302447W WO 2004016580 A3 WO2004016580 A3 WO 2004016580A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
derivatives
amino
gem
diphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2003/002447
Other languages
English (en)
Other versions
WO2004016580A2 (fr
Inventor
Kathleen Clarence-Smith
Jean-Marie Georges Contreras
Laurence Nathalie Deyon
Camille Georges Wermuth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prestwick Pharmaceuticals Inc
Original Assignee
Prestwick Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to UAA200501927A priority Critical patent/UA80559C2/uk
Priority to EA200500333A priority patent/EA010417B1/ru
Priority to KR1020077013426A priority patent/KR100890674B1/ko
Priority to AU2003274213A priority patent/AU2003274213B2/en
Priority to MXPA05001761A priority patent/MXPA05001761A/es
Priority to NZ538633A priority patent/NZ538633A/en
Priority to CA002497347A priority patent/CA2497347A1/fr
Priority to JP2004528582A priority patent/JP2005535715A/ja
Application filed by Prestwick Pharmaceuticals Inc filed Critical Prestwick Pharmaceuticals Inc
Priority to US10/524,869 priority patent/US7488755B2/en
Priority to EP03758195A priority patent/EP1529030A2/fr
Priority to BR0313740-6A priority patent/BR0313740A/pt
Priority to CNA038188481A priority patent/CN1675169A/zh
Publication of WO2004016580A2 publication Critical patent/WO2004016580A2/fr
Publication of WO2004016580A3 publication Critical patent/WO2004016580A3/fr
Priority to IL16677805A priority patent/IL166778A0/xx
Anticipated expiration legal-status Critical
Priority to NO20050961A priority patent/NO20050961L/no
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

On décrit l'utilisation de dérivés de l'acide R(+)-2-amino-3-hydroxypropanoïque, substitué sur l'azote par un groupe (C1-C6)alkyle, (C3-C6)alcényle, 3-oxo(C5-C6)alkyle, 3-oxo(C4-C6)alcén-2-yle, phényl(C1-C6)alkyle, phényl(C2-C6)alcényle, gem-diphényl(C1-C6)alkyle, gem-diphényl(C2-C6)alcényle, (C1-C6)alcanoyle, alanyle éventuellement N-substitué, lysinoyle éventuellement N,N'-disubstitué, phényl(C1-C6)alkylydène ou gem-diphényl(C1-C6)alkylidène, et de leurs sels pharmaceutiquement acceptables pour la préparation de médicaments destinés au traitement de maladies du SNC dues à une transmission glycinergique réduite, notamment au traitement de l'autisme, de la schizophrénie et de la maladie d'Alzheimer.
PCT/FR2003/002447 2002-08-14 2003-08-01 Derives de l'acide r(+)-2-amino-3-hydroxypropanoique a action glycinergique Ceased WO2004016580A2 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
UAA200501927A UA80559C2 (en) 2002-08-14 2003-01-08 The derivatives of r(+)-2-amino-3-hydroxypropanoic acid having the glycinergic action
US10/524,869 US7488755B2 (en) 2002-08-14 2003-08-01 Derivatives of glycinergic R(+)-2-amino-3-hydroxypropanoic acid
AU2003274213A AU2003274213B2 (en) 2002-08-14 2003-08-01 Derivatives of glycinergic R(+)-2-amino-3-hydroxypropanoic acid
MXPA05001761A MXPA05001761A (es) 2002-08-14 2003-08-01 Derivado de acido r(+)-2-amino-3-hidroxipropanoico con accion glicinergica.
NZ538633A NZ538633A (en) 2002-08-14 2003-08-01 R(+)-2-amino-3-hydroxypropanoic acid derivatives with glycinergic action
CA002497347A CA2497347A1 (fr) 2002-08-14 2003-08-01 Derives de l'acide r(+)-2-amino-3-hydroxypropanoique a action glycinergique
JP2004528582A JP2005535715A (ja) 2002-08-14 2003-08-01 グリシン作動性を有するｒ（＋）−２−アミノ−３−ヒドロキシプロピオン酸誘導体
EA200500333A EA010417B1 (ru) 2002-08-14 2003-08-01 Производные r(+)-2-амино-3-гидроксипропионовой кислоты с глицинэргическим действием
EP03758195A EP1529030A2 (fr) 2002-08-14 2003-08-01 Derives de l'acide r(+)-2-amino-3-hydroxypropanoique a action glycinergique
BR0313740-6A BR0313740A (pt) 2002-08-14 2003-08-01 Derivados do ácido r(+)-2-amino-3-hidróxi-propanóico com ação glicinérgica
KR1020077013426A KR100890674B1 (ko) 2002-08-14 2003-08-01 글리신성 ｒ(+)-2-아미노-3-히드록시프로판산 유도체
CNA038188481A CN1675169A (zh) 2002-08-14 2003-08-01 具有甘氨酸能作用的r(+)－2－氨基－3－羟基丙酸衍生物
IL16677805A IL166778A0 (en) 2002-08-14 2005-02-09 Derivatives of gl ycinergic r(+)-2-amino-3-hydroxypropanoic acid
NO20050961A NO20050961L (no) 2002-08-14 2005-02-23 R(+)-2-Amino-3-Hydroksypropansyrederivater med glysinergisk virkning

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR02/10306 2002-08-14
FR0210306A FR2843590B1 (fr) 2002-08-14 2002-08-14 Derives de l'acide r(+)-2-amino-3-hydroxypropanoique a action glycinergique

Publications (2)

Publication Number Publication Date
WO2004016580A2 WO2004016580A2 (fr) 2004-02-26
WO2004016580A3 true WO2004016580A3 (fr) 2004-04-08

Family

ID=30775996

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/002447 Ceased WO2004016580A2 (fr) 2002-08-14 2003-08-01 Derives de l'acide r(+)-2-amino-3-hydroxypropanoique a action glycinergique

Country Status (19)

Country Link
US (1) US7488755B2 (fr)
EP (1) EP1529030A2 (fr)
JP (1) JP2005535715A (fr)
KR (2) KR100756138B1 (fr)
CN (1) CN1675169A (fr)
AU (1) AU2003274213B2 (fr)
BR (1) BR0313740A (fr)
CA (1) CA2497347A1 (fr)
CR (1) CR7736A (fr)
EA (1) EA010417B1 (fr)
FR (1) FR2843590B1 (fr)
GE (1) GEP20074194B (fr)
IL (1) IL166778A0 (fr)
MX (1) MXPA05001761A (fr)
NO (1) NO20050961L (fr)
NZ (1) NZ538633A (fr)
PL (1) PL375413A1 (fr)
UA (1) UA80559C2 (fr)
WO (1) WO2004016580A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013072936A2 (fr) * 2011-11-10 2013-05-23 Ramamohan Rao Davuluri Procédé inédit de préparation de (r)-n-benzyl-2-acétamido-3-méthoxypropionamide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0528172A1 (fr) * 1991-08-08 1993-02-24 J. URIACH & CIA. S.A. Dérivés de (2-alcoyl-3-pyridyl)méthylpipérazine comme antagonistes de PAF
WO1998003472A1 (fr) * 1996-07-23 1998-01-29 Chiesi Farmaceutici S.P.A. Amides d'acide alpha-amino, leur preparation et leur utilisation therapeutique
US5837730A (en) * 1995-12-07 1998-11-17 Javitt; Daniel C. Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists
US6228875B1 (en) * 1998-04-14 2001-05-08 The General Hospital Corporation Methods for treating neuropsychiatric disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03236315A (ja) * 1989-12-05 1991-10-22 Nippon Oil & Fats Co Ltd 抗精神病薬
US5332758A (en) * 1990-07-13 1994-07-26 Kanebo, Ltd. Collagen metabolism ameliorant and its use
GB9425730D0 (en) 1994-12-20 1995-02-22 Nycomed Pharma As Compounds
GB2410947B (en) 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0528172A1 (fr) * 1991-08-08 1993-02-24 J. URIACH & CIA. S.A. Dérivés de (2-alcoyl-3-pyridyl)méthylpipérazine comme antagonistes de PAF
US5837730A (en) * 1995-12-07 1998-11-17 Javitt; Daniel C. Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists
US5854286A (en) * 1995-12-07 1998-12-29 Daniel C. Javitt Treatment of negative and cognitive symptoms of schizophrenia with glycine and its precursors
WO1998003472A1 (fr) * 1996-07-23 1998-01-29 Chiesi Farmaceutici S.P.A. Amides d'acide alpha-amino, leur preparation et leur utilisation therapeutique
US6228875B1 (en) * 1998-04-14 2001-05-08 The General Hospital Corporation Methods for treating neuropsychiatric disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"FORMULAS C6H10N8-C9H13BrPb", CHEMICAL ABSTRACTS (9TH COLLECTIVE INDEX), vol. 76-85, 1972 - 1976, Columbus Ohio,US, pages 2920F, XP002239528 *
CHEMICAL ABSTRACTS, vol. 76, no. 7, 14 February 1972, Columbus, Ohio, US; abstract no. 34561t, A. BALOG ET AL.: "Peptides. XI. Use of Serine N-Protected with beta-Dicarbonyl Compounds in Peptide Synthesis" page 347; column 1; XP002239529 *
REV. ROUM.CHIM., vol. 16, no. 10, 1971, pages 1601 - 1611 *
ROBERT HÄNER ET AL.: "155. Preparation and C-Alkylation of Enantiomerically Pure S-Phenyl Aziridinecarbothioates. On the Structure of Small-Ring Ester Lithium Enolates", HELVETICA CHIMICA ACTA, vol. 70, no. 7, 1987, BASEL CH, pages 1676 - 1693, XP002239526 *
SUSAN E. GIBSON ET AL.: "Synthesis of Conformationally constrained Phenylalanine Analogues via 7-, 8- and 9-endo Heck Cyclisations", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1., no. 4, 1997, CHEMICAL SOCIETY. LETCHWORTH., GB, pages 447 - 455, XP002239527, ISSN: 0300-922X *

Also Published As

Publication number Publication date
PL375413A1 (en) 2005-11-28
KR20070067250A (ko) 2007-06-27
BR0313740A (pt) 2005-07-19
UA80559C2 (en) 2007-10-10
CN1675169A (zh) 2005-09-28
AU2003274213A1 (en) 2004-03-03
NZ538633A (en) 2007-10-26
NO20050961L (no) 2005-04-28
WO2004016580A2 (fr) 2004-02-26
CR7736A (es) 2008-10-10
MXPA05001761A (es) 2005-04-25
FR2843590A1 (fr) 2004-02-20
FR2843590B1 (fr) 2007-10-05
KR20050055697A (ko) 2005-06-13
GEP20074194B (en) 2007-09-10
CA2497347A1 (fr) 2004-02-26
IL166778A0 (en) 2006-01-15
EA200500333A1 (ru) 2005-08-25
KR100756138B1 (ko) 2007-09-05
US7488755B2 (en) 2009-02-10
KR100890674B1 (ko) 2009-03-26
JP2005535715A (ja) 2005-11-24
US20050261372A1 (en) 2005-11-24
EP1529030A2 (fr) 2005-05-11
AU2003274213B2 (en) 2008-03-13
EA010417B1 (ru) 2008-08-29

Similar Documents

Publication Publication Date Title
WO2007110627A3 (fr) Sels de 3,7-diamino-10h-phénothiazine et utilisation correspondante
WO2001028996A3 (fr) Inhibiteurs de neuraminidases
TW200728307A (en) Novel spirochromanone derivatives
NZ517237A (en) 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
BR0314611A (pt) Compostos de tiazol para o tratamento de distúrbios neurodegenerativos
HU229581B1 (en) Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
BRPI0417910A (pt) composto ou um sal ou salvato farmaceuticamente aceitáveis do mesmo, e, uso de um composto
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MX2009004096A (es) Metabolitos de talarozol.
CA2665931C (fr) Derives d'hydrobenzamide en tant qu'inhibiteurs de la proteine hsp90
JO2216B1 (en) 5 chloro-3 (4-methane sulfonyl phenyl) -6-methyl- (2.3)
SI1696905T1 (sl) Substituirani 2-aminotetralini za preventivno zdravljenje Parkinsonove bolezni
PL1697394T3 (pl) Inhibitory COMT
MX2022006990A (es) Forma cristalina de un derivado del acido 7h-benzo[7]anuleno-2-car boxilico.
AU2001274806A1 (en) Sulfonamide derivatives
MXPA05013607A (es) Candidatos de farmaco farmaceuticos mejorados y metodos para preparar los mismos.
SI1751093T1 (sl) Substituirani derivati cikloheksilocetne kisline
WO2005097762A3 (fr) 1,3,4-oxadiazol-2-ones utilises en tant que modulateurs de ppar delta et utilisation associee
WO2004016580A3 (fr) Derives de l'acide r(+)-2-amino-3-hydroxypropanoique a action glycinergique
EP1179342A4 (fr) Compositions medicinales a liberation immediate pour administration orale
MXPA05011521A (es) Derivado de 4,4-difluoro-1,2,3,4-tetrahidro-5h-1-benzazepina o una sal del mismo.
NO20060277L (no) Anvendelse av bisyklo [2.2.1] heptanderivater til fremstilling av nevrobeskyttende farmasoytiske sammensetninger
BR0316751A (pt) Análogos de gabapentina para fibromialgia e outros distúrbios relacionados
TW200517367A (en) Improved pharmaceutical drug candidates and methods for preparation thereof
GEP20115192B (en) Novel indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004528582

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020057002073

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20038188481

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 166778

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2497347

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10524869

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/001761

Country of ref document: MX

Ref document number: 1-2005-500302

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 711/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003274213

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003758195

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 538633

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 200500333

Country of ref document: EA

ENP Entry into the national phase

Ref country code: GE

Ref document number: GE P

WWE Wipo information: entry into national phase

Ref document number: 8683

Country of ref document: GE

Ref document number: 20050084

Country of ref document: UZ

WWE Wipo information: entry into national phase

Ref document number: 375413

Country of ref document: PL

WWP Wipo information: published in national office

Ref document number: 2003758195

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057002073

Country of ref document: KR